It can significantly inhibit the day and night basal gastric acid secretion, and can also inhibit the gastric acid secretion induced by food, histamine, pentagastrin, caffeine and insulin.

This product is a new type of non-narcotic analgesic, with mild antipyretic and muscle relaxant effects. It is effective for moderate and severe pain. An intramuscular injection of 20 mg of this product is equivalent to the effect of 12 mg of morphine. It has a mild respiratory depressant effect. It has no depressant effect on the circulatory system. There is no tolerance and dependence.

It is converted into flavine mononucleotide (FMN) and flavin adenine dinucleotide, both of which are important coenzymes for tissue respiration, and can activate vitamin B6, convert characteristic amino acids into niacin, and may be related to maintaining the integrity of red blood cells.

It is converted into flavine mononucleotide (FMN) and flavin adenine dinucleotide, both of which are important coenzymes for tissue respiration, and can activate vitamin B6, convert characteristic amino acids into niacin, and may be related to maintaining the integrity of red blood cells.

Vitamin B2 is converted into flavin mononucleotide (FMN) and flavin adenine dinucleotide, both of which are important coenzymes for tissue respiration. It can also activate vitamin B6 and convert amino acids into niacin, and may be related to maintaining the integrity of red blood cells.

Vitamin B2 is converted into flavin mononucleotide (FMN) and flavin adenine dinucleotide, both of which are important coenzymes for tissue respiration. It can also activate vitamin B6 and convert amino acids into niacin, and may be related to maintaining the integrity of red blood cells.

Vitamin B2 is converted into flavin mononucleotide (FMN) and flavin adenine dinucleotide, both of which are important coenzymes for tissue respiration. It can also activate vitamin B6 and convert amino acids into niacin, and may be related to maintaining the integrity of red blood cells.

This product is a competitive angiotensin converting enzyme inhibitor, which prevents angiotensin I from being converted into angiotensin II, thereby reducing peripheral vascular resistance and reducing water and sodium retention by inhibiting aldosterone secretion. This product can also dilate peripheral blood vessels by interfering with the degradation of bradykinin. For patients with heart failure, this product can also reduce capillary wedge pressure and pulmonary vascular resistance, increase cardiac output and exercise tolerance time.

This product is a competitive angiotensin converting enzyme inhibitor, which prevents angiotensin I from being converted into angiotensin II, thereby reducing peripheral vascular resistance and reducing water and sodium retention by inhibiting aldosterone secretion. This product can also dilate peripheral blood vessels by interfering with the degradation of bradykinin. For patients with heart failure, this product can also reduce capillary wedge pressure and pulmonary vascular resistance, increase cardiac output and exercise tolerance time.